"MONOCLONAL ANTIBODIES AND IMMUNOASSAY FOR E. COLI TOXIN"

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$500,000.00
Award Year:
1986
Program:
SBIR
Phase:
Phase II
Contract:
n/a
Award Id:
1354
Agency Tracking Number:
1354
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
160 Community Drive, Great Neck, NY, 11021
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
Brandwein
() -
Business Contact:
() -
Research Institute:
n/a
Abstract
RECENT ADVANCES IN BIOCHEMISTRY AND IMMUNOLOGY NOW MAKE POSSIBLE NEW APPROACHES FOR DETECTION AND TREATMENT OF INFECTIOUS DISEASES. OUR GROUP IS COMMITTED TO SUCH TECHNOLOGICAL APPLICATIONS, AND THIS PHASE I PROPOSAL IS IN RESPONSE TO THE STATED INTEREST OF THE N.I.A.D.A. IN SUCH INNOVATIVE BIOMEDICAL TECHNOLOGIES. (DHHS OMNIBUS SOLICITATION, 3/83). SPECIFICALLY, THIS APPLICATION DESCRIBES OUR INTEREST IN DEVELOPING A MONOCLONAL ANTIBODY BASED IMMUNOASSAY FOR THE E. COLI HEAT STABLE ENTER TOXIN (ST), WHICH CAUSES 'TRAVELER'S DIARRHEA IN HUMANS, AND WIDE SPREAD OFTEN FATAL INFECTIOUS DIARRHEA (SCOURS) IN NEWBORN LIVESTOCK. OUR TWO PHASE I GOALS WILL BE 1. TO GENERATE A PANEL OF MURINE MONOCLONAL ANTIBODIES TO THE TOXIN, AND 2. TO COMMENCE DEVELOPMENT OF A SENSITIVE AND VERSATILE ST FLUORESCENCE IMMUNOASSAY. PURIFIED MONOCLONAL ANTIBODIES WILL BE CONJUGATED TO BETA-GALACTOSIDASE AND TESTED IN A HETEROGENEOUS COMPETITIVE ASSAY FORMAT. WE INTEND TO PURSUE SOLID-PHASE METHODS FOR IMMOBILIZATION OF ST-ALBUMIN CONJUGATES, WHICH WILL THEN COMPETE WITH TEST SAMPLE FOR BINDING TO ANTIBODY-ENZYME CONJUGATES. ENZYME ACTIVITY (AND SUBSEQUENTLY, ST CONCENTRATIONS) WILL BE MEASURED IN A FLUORESCENCE ASSAY, MONITORING THE FORMATION OF METHYL-UMBELLIFERONE FROM THE NON-FLUORESCENT SUBSTRATE, METHYL-UMBELLIFERYL GALACTOSIDE. THE FINAL (FLUORESCENCE) MEASUREMENTS CAN BE MADE IN ANY APPROPRIATELY SET FLUORIMETER, OR IN A LOW-COST, PORTABLE PHOTON-COUNTING FLUORIMETER WHICH WE HAVE BEEN DEVELOPING FOR USE WITH SUCH IMMUNOASSAYS. BOTH THE INSTRUMENT AND THE ASSAY FORMAT ARE GEARED TOWARDS RAPID, TECHNICALLY FACILE PERFORMANCE IN A LABORATORY ON 'FIELD' SETTING. DUE TO THE HEALTH AND ECONOMIC IMPACT OF TOXIN RELATED DISEASES, WE BELIEVE THERE ARE SIGNIFICANT HUMAN AND VETERINARY COMMERCIAL MARKETS FOR SUCH A TOXIN DETECTION METHOD, AS WELL AS THE POSSIBLE COMMERCIAL UTILITY OF SUCH ANTIBODIES AS THERAPEUTIC AGENTS. OUR GROUP IS ALSO WELL POSITIONED TO ATTRACT FOLLOW-ON FUNDING FOR THIS PROJECT AND TO DEVELOP/MARKET SUCH COMMERCIAL PRODUCTS. THE TECHNOLOGY DEVELOPED SHOULD ALSO BE APPLICABLE TO OTHER INFECTIOUS DISEASES AND TO THE LONG TERM OBJECTIVES OF N.I.A.I.D. RESEARCH PROGRAM.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government